Skip to content
Screener

Agios Pharmaceuticals AGIO Q2 2025 earnings

Reported July 31, 2025 · Before market open

Revenue$12.5MBeat by $2.2M
EPS-$1.93Miss by $0.19
Revenue estimate$10.3M
EPS estimate-$1.74

Next report

Oct 29, 2026 (in a month)
Revenue estimate$53.8M
EPS estimate-$1.21

Financials

Q2 2025

Income statement

See full
Revenue$12.5M+44.6%
Gross profit$10.8M+51.0%
Operating income-$127.1M-20.1%
Net income-$112.0M-16.5%
EPS (diluted)-$1.93-14.2%

Balance sheet

See full
Cash & equivalents$80.9M-4.3%
Total debt$48.8M-24.5%
Total equity$1.4B+107%
Total assets$1.5B+90.3%

Cash flow

See full
Operating cash flow-$77.1M-6.2%
CapEx$875.0K+454%
Free cash flow-$78.0M-7.2%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.94B-20.9%
Enterprise value$1.9B-21.6%
P/S47.4×-30.8×

Profitability

See full
Gross margin88.2%-1.1pp
Operating margin-1,129.1%-128pp
FCF margin-1,000.7%+19.2pp

Returns & leverage

See full
Debt / equity0×-0.1×
Current ratio14.5×+4.4×

FAQ

When did Agios Pharmaceuticals report Q2 2025 earnings?
Agios Pharmaceuticals (AGIO) reported Q2 2025 earnings on July 31, 2025 before market open.
What were Agios Pharmaceuticals's Q2 2025 revenue and EPS?
Agios Pharmaceuticals reported revenue of $12.5M and eps of $-1.93 for Q2 2025.
Did Agios Pharmaceuticals beat estimates in Q2 2025?
Revenue beat the consensus estimate of $10.3M by $2.2M. EPS missed the consensus estimate of $-1.74 by $0.19.
How did Agios Pharmaceuticals's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 44.6% from $8.6M a year earlier and eps declined 14.2% from $-1.69.
Where can I find Agios Pharmaceuticals's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001439222-25-000087) and the 10-Q periodic report (0001439222-25-000089) directly on SEC EDGAR. The filing index links above go to sec.gov.